Utilization of antiepileptic drugs during pregnancy: Comparative patterns in 38 countries based on data from the EURAP registry
Utilization of antiepileptic drugs during pregnancy: Comparative patterns in 38 countries based on data from the EURAP registry
复制标题
DOI：
10.1111/j.1528-1167.2009.02093.x
复制
发表时间：
2009-10-01
期刊：
影响因子：
5.6
通讯作者：
Vajda, F.
中科院分区：
文献类型：
--
作者：
Battino, D.;Bonizzoni, E.;Vajda, F.
我们评估了1999-2005年来自38个国家的4,798例预期癫痫妊娠患者的抗癫痫药物（AED）使用情况，EURAP是一个国际AED和妊娠登记处。各国的利用模式存在显著差异。第二代AED的暴露范围从印度的3.5%和意大利的7.3%到丹麦的75%。甚至更广泛的变化记录暴露于个别抗癫痫药物。随着时间的推移，第二代AEDs的使用增加（拉莫三嗪，从2001年前的9.9%增加到2003年后的29.6%）。各国使用个别AED的差异可能反映了缺乏关于育龄妇女癫痫最佳治疗的证据，以及各国特定传统、药物成本和药物推广的差异。我们的观察结果强调，需要进行比较研究，以调查妊娠期间AED处方的影响因素，以及它们对妊娠结局的影响。
P>We assessed the utilization of antiepileptic drugs (AEDs), 1999-2005, in 4,798 prospective epilepsy pregnancies from 38 countries participating in EURAP, an international AED and pregnancy registry. Prominent differences in utilization patterns were observed across the various countries. Exposure to second-generation AEDs ranged from 3.5% in India and 7.3% in Italy to 75% in Denmark. Even wider variation was recorded in exposure to individual AEDs. The utilization of second-generation AEDs increased over time (for lamotrigine, from 9.9% of all pregnancies before 2001 to 29.6% after 2003). The differences in use of individual AEDs across countries probably reflect lack of evidence concerning the optimal treatment of epilepsy in women of childbearing age, as well as variation in country-specific traditions, medication costs, and drug promotion. Our observations underscore the need for comparative studies to investigate the factors influencing the prescription of AEDs during pregnancy, as well as their influence on pregnancy outcome.